Martin Vogelbaum is Director at Cara Therapeutics, Inc. (CARA). They have made 5 open-market trades across 1 company since 2014, most recently 2024-06-04.
CIK 0001237624
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $6.4M since 2014, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CARA | SELL | 2022-09-14 | 2022-09-16 | $10.28 | $111K | -9.9% | +6.1% | +11.7% |
| CARA | SELL | 2021-06-07 | 2021-06-07 | $13.05 | $113K | +8.8% | +2.8% | +16.0% |
| CARA | SELL | 2020-11-17 | 2020-11-19 | $16.09 | $97K | -5.5% | -5.2% | +33.7% |
| CARA | BUY | 2016-03-16 | 2016-03-18 | $4.87 | $3.9M | +16.3% | +51.8% | -1.7% |
| CARA | BUY | 2014-02-05 | 2014-02-05 | $11.00 | $2.5M | -32.4% | -0.3% | -0.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.